These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36906604)

  • 1. Feasibility, safety, and acceptability of intranasal heroin-assisted treatment in Switzerland: protocol for a prospective multicentre observational cohort study.
    Westenberg JN; Meyer M; Strasser J; Krausz M; Dürsteler KM; Falcato L; Vogel M
    Addict Sci Clin Pract; 2023 Mar; 18(1):15. PubMed ID: 36906604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and feasibility of intranasal heroin-assisted treatment: 4-week preliminary findings from a Swiss multicentre observational study.
    Vogel M; Meyer M; Westenberg JN; Kormann A; Simon O; Salim Hassan Fadlelseed R; Kurmann M; Bröer R; Devaud N; Sanwald U; Baumgartner S; Binder H; Strasser J; Krausz RM; Beck T; Dürsteler KM; Falcato L
    Harm Reduct J; 2023 Jan; 20(1):2. PubMed ID: 36611162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nasal Opioid Agonist Treatment in Patients with Severe Opioid Dependence: A Case Series.
    Vogel M; Köck P; Strasser J; Kalbermatten C; Binder H; Dürsteler KM; Walter M; Falcato L; Krausz M; Kormann A
    Eur Addict Res; 2022; 28(1):80-86. PubMed ID: 34311466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nasal administration of diacetylmorphine improved the adherence in a patient receiving heroin-assisted treatment.
    Meyer M; Westenberg JN; Strasser J; Dürsteler KM; Lang UE; Krausz M; Vogel M
    Harm Reduct J; 2022 Jun; 19(1):63. PubMed ID: 35672825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of pharmaceutical heroin preparations for medical co-prescription to opioid dependent patients.
    Klous MG; Van den Brink W; Van Ree JM; Beijnen JH
    Drug Alcohol Depend; 2005 Dec; 80(3):283-95. PubMed ID: 15916865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eligibility for heroin-assisted treatment (HAT) among people who inject opioids and are living with HIV in a Canadian setting.
    Klimas J; Dong H; Fairbairn N; Socías E; Barrios R; Wood E; Kerr T; Montaner J; Milloy MJ
    Addict Sci Clin Pract; 2018 Feb; 13(1):3. PubMed ID: 29409539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of heroin-assisted treatment in Norway: protocol for a mixed methods study.
    Myklebust LH; Eide D; Arnevik EA; Dadras O; De Pirro S; Ellefsen R; Fadnes LT; Hesse M; Kvamme TL; Melis F; Oldervoll A; Thylstrup B; Wusthoff LEC; Clausen T
    BMC Health Serv Res; 2024 Mar; 24(1):398. PubMed ID: 38553691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. «One prick and then it´s done»: a mixed-methods exploratory study on intramuscular injection in heroin-assisted treatment.
    Meyer M; Eichenberger R; Strasser J; Dürsteler KM; Vogel M
    Harm Reduct J; 2021 Dec; 18(1):134. PubMed ID: 34922561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supervised Injectable Opioid Treatment for the Management of Opioid Dependence.
    Bell J; Belackova V; Lintzeris N
    Drugs; 2018 Sep; 78(13):1339-1352. PubMed ID: 30132259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged diacetylmorphine take-home during the COVID-19 pandemic-Results of a retrospective cohort study.
    Brezan F; Meyer M; Vogel M; Heimer J; Falcato L; Montagna J; Bruggmann P
    Addiction; 2024 Aug; 119(8):1421-1429. PubMed ID: 38644677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interest in treatment with injectable diacetylmorphine among people who use opioids in Baltimore City, Maryland (USA).
    Allen ST; Schneider KE; Rouhani S; White RH; Morris M; Owczarzak J; Sherman SG
    Ann Med; 2023 Dec; 55(1):2196435. PubMed ID: 37078710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Men's and women's response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder.
    Palis H; Marchand K; Guh D; Brissette S; Lock K; MacDonald S; Harrison S; Anis AH; Krausz M; Marsh DC; Schechter MT; Oviedo-Joekes E
    Subst Abuse Treat Prev Policy; 2017 May; 12(1):25. PubMed ID: 28526048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One size does not fit all-evolution of opioid agonist treatments in a naturalistic setting over 23 years.
    Nordt C; Vogel M; Dey M; Moldovanyi A; Beck T; Berthel T; Walter M; Seifritz E; Dürsteler KM; Herdener M
    Addiction; 2019 Jan; 114(1):103-111. PubMed ID: 30209840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary attitudes on medications for opioid use disorders (MOUDs) in Southeastern Switzerland and New York City.
    Castillo F; Scalise D; Hernandez D; Gupta R; Basaraba CN; Corbeil T; Comer SD; Schneeberger AR
    J Addict Dis; 2023; 41(1):91-97. PubMed ID: 35451354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experiences with take-home dosing in heroin-assisted treatment in Switzerland during the COVID-19 pandemic-Is an update of legal restrictions warranted?
    Meyer M; Strasser J; Köck P; Walter M; Vogel M; Dürsteler KM
    Int J Drug Policy; 2022 Mar; 101():103548. PubMed ID: 34920218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective cohort study on orally administered heroin substitution for severely addicted opioid users.
    Frick U; Rehm J; Kovacic S; Ammann J; Uchtenhagen A
    Addiction; 2006 Nov; 101(11):1631-9. PubMed ID: 17034443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study.
    Rehm J; Gschwend P; Steffen T; Gutzwiller F; Dobler-Mikola A; Uchtenhagen A
    Lancet; 2001 Oct; 358(9291):1417-23. PubMed ID: 11705488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence: A Randomized Clinical Trial.
    Oviedo-Joekes E; Guh D; Brissette S; Marchand K; MacDonald S; Lock K; Harrison S; Janmohamed A; Anis AH; Krausz M; Marsh DC; Schechter MT
    JAMA Psychiatry; 2016 May; 73(5):447-55. PubMed ID: 27049826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substitution treatment for opioid dependence with slow-release oral morphine: Retention rate, health status, and substance use after switching to morphine.
    Lehmann K; Kuhn S; Baschirotto C; Jacobsen B; Walcher S; Görne H; Backmund M; Scherbaum N; Reimer J; Verthein U
    J Subst Abuse Treat; 2021 Aug; 127():108350. PubMed ID: 34134867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrating injectable opioid agonist treatment into a drug treatment court program: A case study.
    Jun JH; Fairbairn N
    Subst Abus; 2018; 39(4):493-496. PubMed ID: 29949453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.